Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Major pollen allergen Ole e 1 (Allergen Ole e I) (allergen Ole e 1)

 ALL1_OLEEU              Reviewed;         145 AA.
P19963; A5A5K8; A5A5K9; A5A5L0; A5A5L1; A5A5L2; A5A5L3; O24166;
O24167; O24168; Q41243; Q5DTB9; Q5DTC0; Q5DTC2; Q5DVQ3; Q5DVQ4;
Q5DVQ5; Q5DVQ6; Q5DVQ7; Q5DVQ9; Q5DVR0; Q5DVR4; Q5DVR6; Q5DVS1;
Q5DVS3;
01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
01-OCT-1993, sequence version 2.
10-MAY-2017, entry version 89.
RecName: Full=Major pollen allergen Ole e 1;
AltName: Full=Allergen Ole e I;
AltName: Allergen=Ole e 1;
Olea europaea (Common olive).
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; Gunneridae;
Pentapetalae; asterids; lamiids; Lamiales; Oleaceae; Oleeae; Olea.
NCBI_TaxID=4146;
[1]
PROTEIN SEQUENCE.
TISSUE=Pollen;
PubMed=8404906; DOI=10.1111/j.1432-1033.1993.tb18208.x;
Villalba M., Batanero E., Lopez-Otin C., Sanchez L.M., Monsalve R.I.,
Gonzalez de la Pena M.A., Lahoz C., Rodriguez R.;
"The amino acid sequence of Ole e I, the major allergen from olive
tree (Olea europaea) pollen.";
Eur. J. Biochem. 216:863-869(1993).
[2]
NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS OLE E I.2; OLE E I.3 AND OLE
E I.4.
TISSUE=Pollen;
PubMed=8195158;
Villalba M., Batanero E., Monsalve R.I., Gonzalez de la Pena M.A.,
Lahoz C., Rodriguez R.;
"Cloning and expression of Ole e I, the major allergen from olive tree
pollen. Polymorphism analysis and tissue specificity.";
J. Biol. Chem. 269:15217-15222(1994).
[3]
NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS OLE E 1.0102; OLE E 1.0103
AND OLE E 1.0105.
TISSUE=Pollen;
PubMed=9314349; DOI=10.1016/S0091-6749(97)70250-1;
Asturias J.A., Arilla M.C., Gomez-Bayon N., Martinez J., Martinez A.,
Palacios R.;
"Cloning and expression of the panallergen profilin and the major
allergen (Ole e 1) from olive tree pollen.";
J. Allergy Clin. Immunol. 100:365-372(1997).
[4]
PROTEIN SEQUENCE OF 1-28, AND VARIANTS.
TISSUE=Pollen;
PubMed=2241952; DOI=10.1016/0006-291X(90)90704-Q;
Villalba M., Lopez-Otin C., Martin-Orozco E., Monsalve R.I.,
Palomino P., Lahoz C., Rodriguez R.;
"Isolation of three allergenic fractions of the major allergen from
Olea europea pollen and N-terminal amino acid sequence.";
Biochem. Biophys. Res. Commun. 172:523-528(1990).
[5]
NUCLEOTIDE SEQUENCE [MRNA] OF 6-145, AND VARIANTS.
STRAIN=cv. Rowghani, and Zard;
PubMed=23454775;
Soleimani A., Morales S., Jimenez-Lopez J.C., Castro A.J.,
Rodriguez-Garcia M.I., de Dios Alche J.;
"Differential expression and sequence polymorphism of the olive pollen
allergen Ole e 1 in two Iranian cultivars.";
Iran. J. Allergy Asthma Immunol. 12:18-28(2013).
[6]
NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 14-145, AND VARIANTS.
STRAIN=cv. Acebuche, cv. Arbequina, cv. Bella de Espana,
cv. Hojiblanca, cv. Loaime, cv. Lucio, cv. Menara,
cv. Picholine marocaine, and cv. Picual;
PubMed=18218146; DOI=10.1186/1471-2229-8-10;
Hamman-Khalifa A., Castro A.J., Jimenez-Lopez J.C.,
Rodriguez-Garcia M.I., Alche J.D.;
"Olive cultivar origin is a major cause of polymorphism for Ole e 1
pollen allergen.";
BMC Plant Biol. 8:10-10(2008).
[7]
NUCLEOTIDE SEQUENCE [MRNA] OF 16-145, AND GLYCOSYLATION.
TISSUE=Pollen;
PubMed=7982126; DOI=10.1111/j.1365-2222.1994.tb00988.x;
Lombardero M., Barbas J.A., del Prado J., Carreira J.;
"cDNA sequence analysis of the main olive allergen, Ole e I.";
Clin. Exp. Allergy 24:765-770(1994).
[8]
PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS.
PubMed=10667857; DOI=10.1034/j.1399-3011.2000.00138.x;
Gonzalez E., Monsalve R.I., Puente X.S., Villalba M., Rodriguez R.;
"Assignment of the disulfide bonds of Ole e 1, a major allergen of
olive tree pollen involved in fertilization.";
J. Pept. Res. 55:18-23(2000).
[9]
CHARACTERIZATION.
PubMed=9641567; DOI=10.1046/j.1365-2222.1998.00190.x;
Cardaba B., Del Pozo V., Jurado A., Gallardo S., Cortegano I.,
Arrieta I., Del Amo A., Tramon P., Florido F., Sastre J., Palomino P.,
Lahoz C.;
"Olive pollen allergy: searching for immunodominant T-cell epitopes on
the Ole e 1 molecule.";
Clin. Exp. Allergy 28:413-422(1998).
[10]
DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
PubMed=10393806;
Alche J.D., Castro A.J., Olmedilla A., Fernandez M.C., Rodriguez R.,
Villalba M., Rodriguez-Garcia M.I.;
"The major olive pollen allergen (Ole e I) shows both gametophytic and
sporophytic expression during anther development, and its synthesis
and storage takes place in the RER.";
J. Cell Sci. 112:2501-2509(1999).
[11]
GLYCAN STRUCTURE.
PubMed=10753962; DOI=10.1074/jbc.275.15.11451;
van Ree R., Cabanes-Macheteau M., Akkerdaas J., Milazzo J.-P.,
Loutelier-Bourhis C., Rayon C., Villalba M., Koppelman S.,
Aalberse R., Rodriguez R., Faye L., Lerouge P.;
"Beta(1,2)-xylose and alpha(1,3)-fucose residues have a strong
contribution in IgE binding to plant glycoallergens.";
J. Biol. Chem. 275:11451-11458(2000).
[12]
DEVELOPMENTAL STAGE, AND SUBCELLULAR LOCATION.
PubMed=15509837; DOI=10.1093/pcp/pch127;
Alche J.D., M'rani-Alaoui M., Castro A.J., Rodriguez-Garcia M.I.;
"Ole e 1, the major allergen from olive (Olea europaea L.) pollen,
increases its expression and is released to the culture medium during
in vitro germination.";
Plant Cell Physiol. 45:1149-1157(2004).
[13]
MUTAGENESIS OF VAL-8; SER-9; GLN-10; PHE-11; PHE-26; GLU-29; LEU-30;
GLU-32; PHE-33; ILE-34; GLY-49; ASP-50; VAL-51; GLU-55; VAL-56;
GLY-57; TYR-58; THR-59; ARG-60; TYR-65; MET-67; GLU-70; LEU-107;
ASN-108; THR-109; VAL-110; GLY-112; PRO-119; LEU-120; PHE-123;
LYS-125; GLN-133; VAL-134; TYR-135; ASN-136; LYS-137; LEU-138;
GLY-139; MET-140; TYR-141 AND PRO-142, AND CHARACTERIZATION OF VARIANT
ALA-28.
PubMed=15941589; DOI=10.1016/j.molimm.2005.04.015;
Gonzalez E.M., Villalba M., Quiralte J., Batanero E., Roncal F.,
Albar J.P., Rodriguez R.;
"Analysis of IgE and IgG B-cell immunodominant regions of Ole e 1, the
main allergen from olive pollen.";
Mol. Immunol. 43:570-578(2006).
[14]
MUTAGENESIS OF TYR-141; 136-ASN--MET-145 AND 141-TYR--MET-145, AND
ALLERGEN.
PubMed=17250698; DOI=10.1111/j.1365-2222.2006.02632.x;
Marazuela E.G., Rodriguez R., Barber D., Villalba M., Batanero E.;
"Hypoallergenic mutants of Ole e 1, the major olive pollen allergen,
as candidates for allergy vaccines.";
Clin. Exp. Allergy 37:251-260(2007).
[15]
GLYCOSYLATION, AND VARIANT ILE-106.
STRAIN=cv. Villacidro;
PubMed=18510354; DOI=10.1021/pr700855u;
Napoli A., Aiello D., Di Donna L., Moschidis P., Sindona G.;
"Vegetable proteomics: the detection of Ole e 1 isoallergens by
peptide matching of MALDI MS/MS spectra of underivatized and
dansylated glycopeptides.";
J. Proteome Res. 7:2723-2732(2008).
[16]
REVIEW, AND NOMENCLATURE.
PubMed=22385802; DOI=10.1016/j.talanta.2012.01.016;
Esteve C., Montealegre C., Marina M.L., Garcia M.C.;
"Analysis of olive allergens.";
Talanta 92:1-14(2012).
-!- FUNCTION: May be involved in recognition between pollen-stigma and
pollen tube-style cells.
-!- SUBCELLULAR LOCATION: Endoplasmic reticulum. Secreted.
-!- TISSUE SPECIFICITY: Expressed in tapetum and pollen grains. Not
detected in petals, roots or leaves.
{ECO:0000269|PubMed:10393806}.
-!- DEVELOPMENTAL STAGE: Expressed at late stages of pollen
development. Up-regulated during pollen germination and pollen
tube growth. {ECO:0000269|PubMed:10393806,
ECO:0000269|PubMed:15509837}.
-!- DOMAIN: Regions 91-102 and 109-130 are immunodominant T-cell
epitopes. Mutations in the C-terminus (135-145) reduce allergenic
activity but do not change the ability to stimulate allergen-
specific T-cells.
-!- PTM: N-glycosylated; contains high mannose (Man(7)-GlcNAc) and
partially fucosylated complex glycans (GlcNAc-Man(3)-Xyl-GlcNAc).
Complex glycans may contribute to the antigenicity. Exists both in
a glycosylated and in a non-glycosylated form. Ole e 1 and Ole e
1.0103 are the only non-glycosylated isoallergens.
-!- PTM: A second potential glycosylation site exists at position 50
in cv. Bella de Espana and cv. Hojiblanca.
-!- POLYMORPHISM: Several isoforms of the allergen exist due to
polymorphism.
-!- ALLERGEN: Causes an allergic reaction in human. Major allergen
from olive pollen. Important in Mediterranean countries.
{ECO:0000269|PubMed:17250698}.
-!- MISCELLANEOUS: Replacement of several other amino acids by Ala has
little or no effect on IgG binding.
-!- SIMILARITY: Belongs to the Ole e I family. {ECO:0000305}.
-!- SEQUENCE CAUTION:
Sequence=CAA73036.1; Type=Erroneous initiation; Evidence={ECO:0000305};
Sequence=CAA73037.1; Type=Erroneous initiation; Evidence={ECO:0000305};
Sequence=CAA73038.1; Type=Erroneous initiation; Evidence={ECO:0000305};
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; Y12426; CAA73036.1; ALT_INIT; mRNA.
EMBL; Y12427; CAA73037.1; ALT_INIT; mRNA.
EMBL; Y12428; CAA73038.1; ALT_INIT; mRNA.
EMBL; AF500908; AAQ07442.1; -; mRNA.
EMBL; AF515277; AAQ08186.1; -; mRNA.
EMBL; AF515278; AAQ08187.1; -; mRNA.
EMBL; AF515279; AAQ08188.1; -; mRNA.
EMBL; AF515280; AAQ08189.1; -; mRNA.
EMBL; AF515281; AAQ08190.1; -; mRNA.
EMBL; AF532753; AAQ10267.1; -; mRNA.
EMBL; AF532754; AAQ10268.1; -; mRNA.
EMBL; AF532755; AAQ10269.1; -; mRNA.
EMBL; AF532756; AAQ10270.1; -; mRNA.
EMBL; AF532757; AAQ10271.1; -; mRNA.
EMBL; AF532758; AAQ10272.1; -; mRNA.
EMBL; AF532759; AAQ10273.1; -; mRNA.
EMBL; AF532760; AAQ10274.1; -; mRNA.
EMBL; AF532761; AAQ10275.1; -; mRNA.
EMBL; AF532762; AAQ10276.1; -; mRNA.
EMBL; AF532763; AAQ10277.1; -; mRNA.
EMBL; AF532764; AAQ10278.1; -; mRNA.
EMBL; AF532765; AAQ10279.1; -; mRNA.
EMBL; AF532766; AAQ10280.1; -; mRNA.
EMBL; AF532767; AAQ10281.1; -; mRNA.
EMBL; AY137467; AAN18042.1; -; mRNA.
EMBL; AY137468; AAN18043.1; -; mRNA.
EMBL; AY137469; AAN18044.1; -; mRNA.
EMBL; AY159880; AAO22132.1; -; Genomic_DNA.
EMBL; AY159881; AAO22133.1; -; Genomic_DNA.
EMBL; EF541386; ABP58632.1; -; mRNA.
EMBL; EF541387; ABP58633.1; -; mRNA.
EMBL; EF541388; ABP58634.1; -; mRNA.
EMBL; EF541389; ABP58635.1; -; mRNA.
EMBL; EF541390; ABP58636.1; -; mRNA.
EMBL; EF541391; ABP58637.1; -; mRNA.
EMBL; S75766; AAB32652.2; -; mRNA.
PIR; A36153; A36153.
PIR; A53806; A53806.
PIR; D53806; D53806.
PIR; S36872; S36872.
SMR; P19963; -.
Allergome; 482; Ole e 1.
Allergome; 483; Ole e 1.0101.
Allergome; 487; Ole e 1.0105.
Allergome; 488; Ole e 1.0106.
Allergome; 489; Ole e 1.0107.
UniCarbKB; P19963; -.
GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
GO; GO:0005615; C:extracellular space; IEA:InterPro.
InterPro; IPR006040; Allegen_Ole_e_I_CS.
InterPro; IPR006041; Pollen_Ole_e1_allergen.
PANTHER; PTHR31614:SF23; PTHR31614:SF23; 1.
PROSITE; PS00925; OLEEI; 1.
1: Evidence at protein level;
Allergen; Direct protein sequencing; Disulfide bond;
Endoplasmic reticulum; Glycoprotein; Polymorphism; Secreted.
CHAIN 1 145 Major pollen allergen Ole e 1.
/FTId=PRO_0000215113.
CARBOHYD 111 111 N-linked (GlcNAc...) (complex)
asparagine; alternate.
CARBOHYD 111 111 N-linked (GlcNAc...) (high mannose)
asparagine; alternate.
DISULFID 19 90 {ECO:0000269|PubMed:10667857}.
DISULFID 22 131 {ECO:0000269|PubMed:10667857}.
DISULFID 43 78 {ECO:0000269|PubMed:10667857}.
VARIANT 3 3 I -> V (in Ole e 1.0102, Ole e 1.0103 and
Ole e 1.0105).
VARIANT 8 8 V -> I (in Ole e I.4).
VARIANT 12 12 H -> Y (in Ole e I.4).
VARIANT 13 13 I -> V (in strain: cv. Zard; variant 2.
In Ole e I.4).
VARIANT 14 14 Q -> I (in strain: cv. Bella de Espana;
variants 1 and 2, cv. Loaime, cv. Lucio,
cv. Menara; variants 1 and 2, cv.
Picholine marocaine and cv. Picual;
variant 1).
VARIANT 15 15 G -> L (in strain: cv. Picual; variant
1).
VARIANT 15 15 G -> Q (in strain: cv. Arbequina;
variants 1 and 2 and cv. Bella de Espana;
variant 3).
VARIANT 15 15 G -> R (in strain: cv. Bella de Espana;
variants 1 and 2, cv. Menara; variants 1
and 2 and cv. Picholine marocaine).
VARIANT 15 15 G -> S (in strain: cv. Picual; variant
3).
VARIANT 15 15 G -> W (in strain: cv. Loaime and cv.
Picual; variant 2).
VARIANT 16 16 Q -> A (in strain: cv. Arbequina; variant
1).
VARIANT 16 16 Q -> D (in strain: cv. Arbequina; variant
2, cv. Bella de Espana; variant 3 and cv.
Picual; variant 3).
VARIANT 16 16 Q -> R (in strain: cv. Acebuche).
VARIANT 16 16 Q -> T (in strain: cv. Bella de Espana;
variants 1 and 2, cv. Loaime, cv. Menara;
variants 1 and 2, cv. Picholine marocaine
and cv. Picual; variants 1 and 2).
VARIANT 17 17 V -> I (in strain: cv. Rowghani; variant
3 and cv. Zard; variant 2).
VARIANT 17 17 V -> S (in strain: cv. Arbequina; variant
2, cv. Bella de Espana; variant 3, cv.
Hojiblanca and cv. Picual; variant 3).
VARIANT 17 17 V -> T (in strain: cv. Acebuche).
VARIANT 18 18 Y -> F (in strain: cv. Bella de Espana;
variant 1).
VARIANT 18 18 Y -> H (in strain: cv. Menara; variant
2).
VARIANT 18 18 Y -> S (in strain: cv. Bella de Espana;
variant 2 and cv. Picual; variant 2).
VARIANT 18 18 Y -> V (in strain: cv. Acebuche).
VARIANT 19 19 C -> Q (in strain: cv. Bella de Espana;
variant 2).
VARIANT 19 19 C -> R (in strain: cv. Arbequina; variant
2 and cv. Bella de Espana; variant 1).
VARIANT 19 19 C -> S (in strain: cv. Bella de Espana;
variant 3).
VARIANT 19 19 C -> T (in strain: cv. Acebuche).
VARIANT 20 20 D -> G (in strain: cv. Acebuche and cv.
Bella de Espana; variant 3).
VARIANT 20 20 D -> V (in strain: cv. Bella de Espana;
variant 1).
VARIANT 21 21 T -> H (in strain: cv. Bella de Espana;
variant 3).
VARIANT 21 21 T -> Y (in strain: cv. Acebuche).
VARIANT 23 23 R -> C (in strain: cv. Bella de Espana;
variant 2).
VARIANT 23 23 R -> P.
VARIANT 24 24 A -> S (in strain: cv. Rowghani; variant
3. In Ole e 1.0105).
VARIANT 24 24 A -> T (in Ole e I.4).
VARIANT 25 25 G -> R (in strain: cv. Bella de Espana;
variants 1, 2 and 3 and cv. Rowghani;
variants 3 and 4. In Ole e 1.0105, Ole e
I.3 and Ole e I.4).
VARIANT 28 28 T -> A (in strain: cv. Zard; variant 2;
50% loss of IgG binding).
{ECO:0000269|PubMed:15941589}.
VARIANT 30 30 L -> F (in Ole e I.4).
VARIANT 35 35 P -> L (in strain: cv. Zard; variant 2).
VARIANT 38 38 S -> G (in strain: cv. Bella de Espana;
variants 1, 2 and 3, cv. Hojiblanca and
cv. Zard; variant 2. In Ole e I.4).
VARIANT 39 39 L -> V (in strain: cv. Arbequina;
variants 1 and 2, cv. Bella de Espana;
variants 1, 2 and 3, cv. Hojiblanca, cv.
Loaime, cv. Lucio, cv. Menara; variants 1
and 2, cv. Picholine marocaine, cv.
Picual; variants 1 and 2, cv. Rowghani;
variants 2, 3 and 4 and cv. Zard;
variants 1 and 2. In Ole e 1.0102, Ole e
1.0103, Ole e 1.0105, Ole e I.3 and Ole e
I.4).
VARIANT 44 44 K -> R (in strain: cv. Rowghani; variants
2, 3 and 4 and cv. Zard; variants 1 and
2. In Ole e 1.0105).
VARIANT 45 45 D -> E (in strain: cv. Zard; variant 1
and cv. Rowghani; variants 2 and 3. In
Ole e 1.0105).
VARIANT 46 46 K -> G (in strain: cv. Bella de Espana;
variants 1, 2 and 3, cv. Hojiblanca and
cv. Rowghani; variant 4. In Ole e I.3 and
Ole e I.4).
VARIANT 46 46 K -> I.
VARIANT 46 46 K -> R (in strain: cv. Arbequina;
variants 1 and 2).
VARIANT 46 46 K -> S (in strain: cv. Zard; variant 2).
VARIANT 47 47 E -> K (in strain: cv. Rowghani; variant
2 and cv. Zard; variants 1 and 2).
VARIANT 48 48 N -> K (in strain: cv. Zard; variant 2).
VARIANT 50 50 D -> K (in Ole e I.4).
VARIANT 50 50 D -> N (in strain: cv. Bella de Espana;
variants 1, 2 and 3, cv. Hojiblanca and
cv. Zard; variant 2).
VARIANT 50 50 D -> S (in strain: cv. Rowghani; variant
4. In Ole e I.3).
VARIANT 51 51 V -> I (in strain: cv. Arbequina;
variants 1 and 2, cv. Hojiblanca, cv.
Loaime, cv. Lucio, cv. Menara; variants 1
and 2, cv. Picholine marocaine, cv.
Picual; variants 1 and 2, cv. Rowghani,
variants 2, 3 and 4 and cv. Zard;
variants 1 and 2. In Ole e 1.0105, Ole e
I.3 and Ole e I.4).
VARIANT 56 56 V -> I (in strain: cv. Rowghani; variant
3. In Ole e 1.0102, 1.0103 and 1.0105).
VARIANT 58 58 Y -> S (in strain: cv. Rowghani; variant
4).
VARIANT 69 69 V -> I (in strain: cv. Bella de Espana;
variants 1, 2 and 3, cv. Rowghani;
variant 4 and cv. Zard; variant 2. In Ole
e I.3 and Ole e I.4).
VARIANT 75 75 N -> D (in strain: cv. Rowghani; variant
4. In Ole e I.3).
VARIANT 80 80 I -> V (in strain: cv. Zard; variant 2).
VARIANT 81 81 T -> N (in strain: cv. Zard; variant 2).
VARIANT 82 82 L -> S (in strain: cv. Zard; variant 2).
VARIANT 83 83 I -> L (in strain: cv. Bella de Espana;
variants 1, 2 and 3 and cv. Zard; variant
2. In Ole e I.4).
VARIANT 86 86 G -> S (in strain: cv. Bella de Espana;
variants 1, 2 and 3, cv. Rowghani;
variant 4 and cv. Zard; variant 2. In Ole
e I.3 and Ole e I.4).
VARIANT 87 87 R -> S.
VARIANT 91 91 N -> D (in strain: cv. Arbequina;
variants 1 and 2, cv. Bella de Espana;
variants 1, 2 and 3, cv. Hojiblanca, cv.
Loaime, cv. Picual; variants 1 and 2, cv.
Rowghani; variants 3 and 4 and cv. Zard;
variant 2. In Ole e 1.0105, Ole e I.3 and
Ole e I.4).
VARIANT 95 95 T -> I (in strain: cv. Rowghani; variant
3 and cv. Zard; variant 2. In Ole e
1.0105).
VARIANT 95 95 T -> V (in strain: cv. Bella de Espana;
variants 1, 2 and 3 and cv. Rowghani;
variant 4. In Ole e I.3).
VARIANT 99 99 A -> V (in strain: cv. Acebuche, cv.
Arbequina; variants 1 and 2, cv. Bella de
Espana; variants 1, 2 and 3, cv.
Hojiblanca, cv. Picual; variant 3, cv.
Rowghani; variants 1 and 4 and cv. Zard;
variant 2. In Ole e I.2, Ole e I.3 and
Ole e I.4).
VARIANT 100 100 K -> R (in strain: cv. Zard; variant 2).
VARIANT 103 103 L -> V (in Ole e I.4).
VARIANT 104 104 K -> R (in strain: cv. Zard; variant 2).
VARIANT 106 106 K -> I (in strain: cv. Acebuche, cv.
Arbequina; variant 1 and 2, cv.
Hojiblanca, cv. Loaime, cv. Lucio, cv.
Menara; variants 1 and 2, cv. Picholine
marocaine, cv. Picual; variants 1, 2 and
3, cv. Rowghani; variants 1, 2 and 3 and
cv. Zard; variant 1. In Ole e 1.0102, Ole
e 1.0103, Ole e 1.0105, Ole e I.2 and Ole
e I.4). {ECO:0000269|PubMed:18510354}.
VARIANT 106 106 K -> L (in strain: cv. Zard; variant 2).
VARIANT 106 106 K -> M (in strain: cv. Bella de Espana;
variants 1, 2 and 3 and cv. Rowghani;
variant 4. In Ole e I.3).
VARIANT 108 108 N -> S (in Ole e 1.0103).
VARIANT 111 111 N -> D.
VARIANT 115 115 R -> C (in strain: cv. Zard; variant 2).
VARIANT 117 117 V -> I (in strain: cv. Bella de Espana;
variants 1, 2 and 3, cv. Hojiblanca, cv.
Rowghani; variant 2 and cv. Zard;
variants 1 and 2. In Ole e I.3 and Ole e
I.4).
VARIANT 118 118 N -> K (in strain: cv. Zard; variant 2).
VARIANT 121 121 G -> R (in Ole e 1.0102).
VARIANT 123 123 F -> Y (in strain: cv. Zard; variant 1
and cv. Rowghani; variant 2. In Ole e
1.0102 and Ole e 1.0103).
VARIANT 125 125 K -> N (in strain: cv. Zard; variant 2).
VARIANT 126 126 E -> K (in strain: cv. Zard; variant 2).
VARIANT 132 132 A -> P (in strain: cv. Bella de Espana;
variants 1, 2 and 3, cv. Rowghani;
variant 4 and cv. Zard; variant 2. In Ole
e I.3 and Ole e I.4).
VARIANT 135 135 Y -> F (in strain: cv. Bella de Espana;
variants 1, 2 and 3, cv. Rowghani;
variant 4 and cv. Zard; variant 2. In Ole
e I.3 and Ole e I.4).
VARIANT 139 139 G -> D (in strain: cv. Rowghani; variant
2).
VARIANT 144 144 N -> D (in strain: cv. Bella de Espana;
variants 1, 2 and 3, cv. Rowghani;
variant 4 and cv. Zard; variant 2).
VARIANT 144 144 N -> T (in strain: cv. Picual; variant
3).
VARIANT 145 145 M -> HGMSR (in strain: cv. Acebuche).
VARIANT 145 145 M -> L (in strain: cv. Zard; variant 2).
VARIANT 145 145 M -> WNVTI (in strain: cv. Picual;
variant 3).
MUTAGEN 8 8 V->A: 90% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 9 9 S->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 10 10 Q->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 11 11 F->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 26 26 F->A: 70% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 29 29 E->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 30 30 L->A: 50% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 32 32 E->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 33 33 F->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 34 34 I->A: 50% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 49 49 G->A: 50% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 50 50 D->A: 60% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 51 51 V->A: 50% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 55 55 E->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 56 56 V->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 57 57 G->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 58 58 Y->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 59 59 T->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 60 60 R->A: 60% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 65 65 Y->A: 70% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 67 67 M->A: 50% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 70 70 E->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 107 107 L->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 108 108 N->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 109 109 T->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 110 110 V->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 112 112 G->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 119 119 P->A: 70% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 120 120 L->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 123 123 F->A: Loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 125 125 K->A: 80% loss of IgG binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 133 133 Q->A: 50% loss of IgG binding and 40%
loss if IgE binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 134 134 V->A: 30% loss of IgG binding and 50%
loss if IgE binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 135 135 Y->A: No loss of IgG binding and 40% loss
if IgE binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 136 145 Missing: Decreased IgE binding.
{ECO:0000269|PubMed:17250698}.
MUTAGEN 136 136 N->A: 40% loss of IgG binding and 60%
loss if IgE binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 137 137 K->A: 20% loss of IgG binding and 80%
loss if IgE binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 138 138 L->A: 70% loss of IgG binding and 90%
loss if IgE binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 139 139 G->A: 30% loss of IgG binding and 90%
loss if IgE binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 140 140 M->A: 50% loss of IgG binding and 50%
loss if IgE binding.
{ECO:0000269|PubMed:15941589}.
MUTAGEN 141 145 Missing: Decreased IgE binding.
{ECO:0000269|PubMed:17250698}.
MUTAGEN 141 141 Y->A: 90% loss of IgG binding and 95%
loss if IgE binding.
{ECO:0000269|PubMed:15941589,
ECO:0000269|PubMed:17250698}.
MUTAGEN 142 142 P->A: 20% loss of IgG binding and 95%
loss if IgE binding.
{ECO:0000269|PubMed:15941589}.
SEQUENCE 145 AA; 16330 MW; 3F11F04E01C12C84 CRC64;
EDIPQPPVSQ FHIQGQVYCD TCRAGFITEL SEFIPGASLR LQCKDKENGD VTFTEVGYTR
AEGLYSMLVE RDHKNEFCEI TLISSGRKDC NEIPTEGWAK PSLKFKLNTV NGTTRTVNPL
GFFKKEALPK CAQVYNKLGM YPPNM


Related products :

Catalog number Product name Quantity
A6015 Fish Allergen Extraction Kit 1 (24 tubes) - ALLERGEN-CHECK ELISA PRODUCTS
GTX28354 House Dust Mite Allergen (D. farinae) 15K Allergen (DfA) 100 µg
AS-AM1 Amb a 1 POLLEN ALLERGEN 1sample
AS-BV1 Bet v 1 POLLEN ALLERGEN 1 sample
AS-PP5 Phl p 5 POLLEN ALLERGEN 1 sample
EL-BV1 Bet v 1 ELISA-10 POLLEN ALLERGEN 1 kit
EL-PP5 Phl p 5 ELISA-10 POLLEN ALLERGEN 1 kit
EL-AM1 Amb a 1 ELISA-10 POLLEN ALLERGEN 1 kit
A6015 Allergen Extraction Kit 1 for Fish-Check ELISA 4.5ml_tube of allergen extraction solution with yellow dye 24 tubes
NA-AAR1-1 Natuarl Amb a 1 POLLEN ALLERGEN 250
RP-OE1-1 rOle e 1 (Olive) Recombinant POLLEN ALLERGEN 250
RE-PP6-1 rPhl p 6 (Timothy) Recombinant POLLEN ALLERGEN 250
RE-PP2-1 rPhl p 2 (Timothy) Recombinant POLLEN ALLERGEN 250
RE-BV2-1 rBet v 2 (Birch) Recombinant POLLEN ALLERGEN 250
RE-PP7-1 rPhl p 7 (Timothy) Recombinant POLLEN ALLERGEN 250
BETV1d5-R-100 Recombinant purified allergen 1 of birch pollen, Betula verrucosa Isoform Bet v 1.0401 100 ug
BETV1a5-R-100 Recombinant purified allergen 1 of birch pollen, Betula verrucosa, Isoform Bet v 1.0101 1 mg
BETV1a5-R-100 Recombinant purified allergen 1 of birch pollen, Betula verrucosa, Isoform Bet v 1.0101 100 ug
ALNG15-R-100 Recombinant purified allergen 1 of alder pollen, Alnus glutinos, Isoform Aln g 1.0101 100 ug
BETV1d5-R-100 Recombinant purified allergen 1 of birch pollen, Betula verrucosa Isoform Bet v 1.0401 1 mg
CORA15-R-100 Recombinant purified allergen 1 of hazel pollen, Corylus avellana, Isoform Cor a 1.0103 1 mg
CORA15-R-100 Recombinant purified allergen 1 of hazel pollen, Corylus avellana, Isoform Cor a 1.0103 100 ug
ALNG15-R-100 Recombinant purified allergen 1 of alder pollen, Alnus glutinos, Isoform Aln g 1.0101 1 mg
BETV25-R-100 Recombinant purified allergen 2 of birch pollen, profilin, Betula verrucosa Isoform Bet v 2.0101 100 ug
BETV25-R-100 Recombinant purified allergen 2 of birch pollen, profilin, Betula verrucosa Isoform Bet v 2.0101 1 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur